Cabozantinib is an orally administered tyrosine kinase inhibitor designed to interfere with signaling pathways that tumors use to grow, invade surrounding tissues and recruit blood vessels. Its molecular targets include vascular endothelial growth factor receptors, particularly VEGFR2, as well as MET and AXL, proteins associated with angiogenesis, metastatic behavior and resistance to therapy. By blocking these kinases, cabozantinib can disrupt both the cancer cell and the tumor microenvironment. The drug has become an established treatment in several oncology settings, including renal cell carcinoma and selected thyroid and liver cancers, making it a valuable starting point for further medicinal-chemistry innovation.

Zanzalintinib, also known as XL092 during its development, belongs to the same broad family of kinase inhibitors but is not simply cabozantinib under a new name. It is an investigational compound built around the idea that carefully selected structural adjustments can alter a molecule’s biological profile without abandoning the pharmacological logic that made its predecessor effective. The central scientific question is not whether the new molecule looks radically different, but whether small changes can tune properties such as target selectivity, tissue distribution, metabolic stability, dosing behavior and tolerability.

That distinction is crucial in kinase drug design. A compound can bind several enzymes with related structures, but the strength and duration of those interactions may vary significantly after even modest chemical editing. Changes to substituents, hydrogen-bonding groups, ring systems or the molecule’s three-dimensional shape can influence how tightly it fits into a kinase’s ATP-binding pocket. They can also affect how rapidly the liver metabolizes the compound, how it crosses cell membranes and how long therapeutically useful concentrations remain in the bloodstream. In oncology, where treatment may continue for months or years, these pharmacological details can determine whether a promising mechanism becomes a practical medicine.

The cabozantinib-to-zanzalintinib story therefore illustrates a form of molecular optimization that is more subtle than the discovery of an entirely new chemical class. Instead of starting from an empty research program, scientists can use an existing drug as a map of validated biology. The original medicine identifies pathways worth targeting, reveals clinically relevant exposure levels and provides information about toxicities and resistance. Researchers can then modify the structure to seek a different balance between potency and safety. The result may retain the parent drug’s therapeutic rationale while opening opportunities for new combinations, disease settings or treatment schedules.

The authors describe this approach as a new frontier in product hopping because the modifications can be chemically obvious in retrospect yet strategically important in practice. “Obvious” does not mean effortless. Medicinal chemistry often advances through hundreds or thousands of analogues, each differing by a small change, before one achieves the desired combination of activity, selectivity and drug-like behavior. A fluorine atom, an altered linker or a replacement ring can change a molecule’s electronic properties, shape and interaction with proteins. The challenge is to identify which apparently minor edits produce a meaningful clinical advantage rather than merely a cosmetic variation.

The commercial implications are substantial. A follow-on molecule based on an established drug can benefit from years of prior biological knowledge, manufacturing experience and clinical precedent. At the same time, it may create new intellectual-property positions and support a fresh development program as the original product approaches the limits of its patent life or market opportunity. For companies, this can reduce some of the uncertainty associated with discovering a medicine from scratch. For patients, the strategy could produce compounds that are easier to tolerate, more convenient to administer or better suited to combination therapy. But it also raises a longstanding question: when does a genuine therapeutic improvement become little more than a commercial extension of an existing product?

That question is especially important for targeted cancer medicines, because their clinical value depends on more than laboratory potency. A new kinase inhibitor must demonstrate that its altered profile translates into improved outcomes, manageable adverse effects or meaningful activity in patients whose tumors have stopped responding to earlier treatments. If zanzalintinib can offer a distinct balance of VEGFR, MET and TAM-family kinase activity, for example, its potential may lie not only in replacing cabozantinib but also in being paired with immunotherapies or other targeted agents. Such combinations require careful attention to overlapping toxicities, pharmacokinetic interactions and the biological consequences of simultaneously suppressing several signaling networks.

The case also highlights how modern drug development increasingly blurs the boundaries between innovation and refinement. Breakthroughs do not always arrive as entirely new molecular architectures. Sometimes they emerge from a disciplined re-examination of a known scaffold, guided by structural biology, computational modeling, pharmacology and clinical experience. The authors’ analysis suggests that the next generation of pharmaceutical competition may be shaped by these “obvious” modifications: changes that appear small on the page but can redirect a drug’s behavior inside the body. Whether that strategy delivers genuine progress will ultimately depend on evidence from clinical trials, not on chemical novelty alone.

Subject of Research: Product hopping and medicinal-chemistry optimization in the development of zanzalintinib from cabozantinib.

Article Title: From cabozantinib to zanzalintinib: obvious chemical modifications as a new frontier in product hopping.

Article References: Strohbehn, G.W., Tu, S.S., Wang, X. et al. From cabozantinib to zanzalintinib: obvious chemical modifications as a new frontier in product hopping. Nat Biotechnol 44, 1274–1279 (2026). https://doi.org/10.1038/s41587-026-03242-w

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03242-w

Keywords: Cabozantinib, zanzalintinib, product hopping, medicinal chemistry, tyrosine kinase inhibitors, cancer therapeutics, drug development, pharmaceutical innovation.

The main protease of SARS-CoV-2 plays a crucial role in the viral life cycle by processing polyproteins into functional proteins necessary for viral replication. Targeting this protease has become a focal point for drug development, as inhibiting its function can significantly disrupt the replication of the virus. The research team systematically designed and synthesized these new derivatives with the intent of blocking this protease’s activity, thereby providing a promising avenue for therapeutic intervention.

In constructing these 2-arylthiomethyl-6-bromoindole derivatives, the researchers employed strategic molecular design principles aimed at optimizing the interaction with the target protease. Various chemical modifications were made to the indole core structure, which is known for its biological versatility. This careful approach allowed the scientists to create compounds that not only possess the potential to bind effectively to the protease but also exhibit favorable pharmacological profiles, enhancing their viability as candidates for further development.

During the synthesis phase, the team utilized robust organic chemistry techniques, employing both known and innovative methodologies to create a library of compounds. Each synthesized derivative underwent rigorous analytical characterization, ensuring that their structures were confirmed before proceeding to biological testing. This meticulous approach reflects the researchers’ commitment to high standards and reproducibility, which are vital in drug discovery processes.

Biological evaluation was performed to assess the inhibitory activity of these derivatives against the SARS-CoV-2 main protease. To measure this activity, the researchers employed enzymatic assays that quantify the extent to which each compound could inhibit protease function. The results demonstrated that several of the synthesized derivatives exhibited promising inhibitory activity, significantly outperforming existing inhibitors in some cases, thus validating the hypothesis that these new compounds could serve as effective therapeutic agents.

Moreover, the researchers explored the structure-activity relationships (SAR) within their compound library. By correlating specific structural features with the observed biological activity, they identified key molecular attributes that enhance inhibitory efficacy. These insights are not only crucial for the current study but will also inform future medicinal chemistry efforts in designing next-generation protease inhibitors, broadening the scope of therapeutic options available for COVID-19.

Safety and toxicity assessments are paramount in the evaluation of potential drug candidates. The team undertook preliminary studies to assess the cytotoxicity of their derivatives using various mammalian cell lines. Preliminary results indicated that the derivatives displayed favorable safety profiles, raising confidence regarding their future therapeutic applications. Further studies will be necessary to fully elucidate any potential adverse effects and to ensure that the compounds can be administered safely in vivo.

The findings presented in this research are particularly timely and relevant, given the ongoing public health challenges posed by COVID-19. As novel variants of SARS-CoV-2 continue to emerge, the demand for effective antiviral therapies remains critical. The approach taken by Zhang, Li, Liu, and their colleagues exemplifies the significant contributions that fundamental research can make towards addressing real-world health crises, providing hope for better treatment strategies.

Throughout the study, the authors emphasized the importance of collaborative efforts in science, highlighting how interdisciplinary teamwork enables more innovative solutions to complex problems like pandemic response. The fusion of expertise in organic chemistry, molecular biology, and pharmacology underscored the multidisciplinary nature of contemporary drug discovery and development.

As the research progresses, the next steps will involve further optimization of the most promising derivative candidates. This could entail refining their pharmacokinetic and pharmacodynamic properties, ensuring that they can achieve effective concentrations at the site of action while minimizing side effects. The iterative nature of drug development is a hallmark of successful therapeutic innovation.

In conclusion, the groundbreaking work by Zhang and colleagues offers a roadmap for future antiviral drug development, specifically against SARS-CoV-2. By unveiling the inhibitory activities of 2-arylthiomethyl-6-bromoindole derivatives, they have made significant strides toward the goal of producing effective treatments for COVID-19. With ongoing research, further validation, and clinical trials, these derivatives could soon represent a novel class of antiviral agents ready to combat ongoing and future global health threats.

As the world navigates the complexities of the COVID-19 pandemic, it is critical to support ongoing scientific research efforts. The results from this study are a testament to the power of targeted drug design in addressing viral diseases and highlight the potential for chemistry and biology to come together in the fight against infections that threaten public health worldwide.

The journey to a new antiviral treatment is fraught with challenges, but the dedication and innovation demonstrated in this research signify a step forward. The scientific community is clearly mobilized, and such studies serve to inspire future generations of researchers as they take on the vital task of protecting global populations from infectious diseases.

Subject of Research: Inhibition of SARS-CoV-2 main protease using 2-arylthiomethyl-6-bromoindole derivatives.

Article Title: Design, synthesis and SARS-CoV‑2 main protease inhibitory activities of 2-arylthiomethyl-6-bromoindole derivatives.

Article References:

Xinyu, Z., Xiaoyang, L., Shiyu, L. et al. Design, synthesis and SARS-CoV‑2 main protease inhibitory activities of 2-arylthiomethyl-6-bromoindole derivatives.
Mol Divers (2025). https://doi.org/10.1007/s11030-025-11308-1

Image Credits: AI Generated

DOI:

Keywords: SARS-CoV-2, main protease, inhibitors, antiviral therapy, medicinal chemistry, structure-activity relationship.